This document provides a summary of bleeding esophageal varices and recommendations for treatment with Terlipressin (Thinwes). It discusses that portal hypertension from liver cirrhosis can cause esophageal varices, which have a high risk of bleeding. Terlipressin is recommended for managing acute bleeding of esophageal varices as it decreases portal blood flow and pressure. The document reviews market trends, competitors, pricing, and positioning of Thinwes for the treatment of bleeding esophageal varices and hepatorenal syndrome.
This document provides a summary of bleeding esophageal varices and recommendations for treatment with Terlipressin (Thinwes). It discusses that portal hypertension from liver cirrhosis can cause esophageal varices, which have a high risk of bleeding. Terlipressin is recommended for managing acute bleeding of esophageal varices as it decreases portal blood flow and pressure. The document reviews market trends, competitors, pricing, and positioning of Thinwes for the treatment of bleeding esophageal varices and hepatorenal syndrome.
This document provides a summary of bleeding esophageal varices and recommendations for treatment with Terlipressin (Thinwes). It discusses that portal hypertension from liver cirrhosis can cause esophageal varices, which have a high risk of bleeding. Terlipressin is recommended for managing acute bleeding of esophageal varices as it decreases portal blood flow and pressure. The document reviews market trends, competitors, pricing, and positioning of Thinwes for the treatment of bleeding esophageal varices and hepatorenal syndrome.
TOPIC OF THE MONTH BLEEDING OESOPHAGEAL VARICES: A MEDICAL BRIEF SNAPSHOT Portal hypertension is a major complication of chronic liver disease. In cirrhosis, architectural distortion of the liver causes an increase in the intrahepatic vascular resistance. Gastro-oesophageal varices form as a result of increased portal pressure, the product of increased portal venous inflow and resistance to outflow from the portal venous system Gastro-oesophageal varices are present in almost half of patients at the time of the diagnosis of cirrhosis The 6-week mortality for variceal bleeding is approximately 10%, and the 1-year recurrence rate of variceal bleeding is 60% 1 4 2 3 BOV & HRS : A Major complications of Cirrhosis CURRENT RECOMMENDED MANAGEMENT OF PATIENTS WITH ACUTE VARICEAL BLEEDING ROLE OF THINWES Indications Indications In the management of : Bleeding Oesophageal Varices Hepato Renal Syndrome Pharmacological Benefits significantly decreases portal venous flow Decrease hepatic venous pressure gradient & mortality Terlipressin & Albumin significantly decreases serum creatinine levels & improves renal function. Dosage Bleeding Oesophageal Varices is 2mg IV bolus every 4-6hrs which can be continued upto a maximum of 72 hrs. In Hepato renal Syndrome, the dosage is 1-2mg bolus every 4-6 hrs maximun of 2mg every 4- 6 hrs. MECHANISM OF ACTION THINWES ADVANTAGES Highly efficacious in BOV with better survival rates which makes Terlipressin a drug of choice amongst clinicians Well documented benefits in Hepato Renal Syndrome Single shot bolus every 4-6 hours No Tachyphylaxis or desensitization with repeated dose Lesser hospital stay MARKET TREND Brand Company Sum of MAT (May 13) Sum of MAT (May 14) TERLYZ SUN* 7.7 8.9 TERLIFORCE ALEMBIC 3.4 3.1 THINWES BIOCON 0.8 3 TERLISTAT SAMARTH PHARMA 2 1.8 T-PRESSIN UNITED BIOTECH 0 0.9 REMESTYP FERRING PHARMA 0.7 0.4 TERLIBAX RANBAXY* 0 0.1 TRIPEZ UNIQUE PHARM 0.2 0.1 TRESIL SERUM INSTITUTE 0 0 TOTAL 14.7 18.2 Total competitors: 9 Total Market Value: 18.2 Growth: 24% COMPETITOR MARKET OVERVIEW TERLYZ 49% TERLIFORCE 17% THINWES 16% TERLISTAT 10% T-PRESSIN 5% REMESTYP 2% TERLIBAX 1% OTHER 0% Brand Company Growth Volume led growth (VLG) Price led growth (PLG) TERLYZ SUN* 15% 12% 3% TERLIFORCE ALEMBIC -10% -11% 1% THINWES BIOCON 255% 255% 0% TERLISTAT SAMARTH PHARMA -8% 14% -22% T-PRESSIN UNITED BIOTECH - - - REMESTYP FERRING PHARMA -32% -32% 0% TERLIBAX RANBAXY* - - - COMPETITOR PRICE INSIGHTS Brand MRP Thinwes (1 mg/10 ml) 2000/- Terlyz (1 mg/10 ml) 1380/- Remestyp 2000/- BRAND SEGMENTATION AND POSITIONING Strength Packing MRP (per vial) Terlipressin inj. 1 mg 1mg / 10 ml vial 2000 THINWES PACKAGING AND PRICING Speciality Targeting Positioning Targeted Drs/ TBM Indication Gastroenterol ogists (Surg. & Physicians) All BOV Ceases Bleeding, Restores Life Hepatologists All BOV Intensivists All BOV, HRS Con. Physicians 20 BOV, HRS BRAND INSIGHTS